Saturday 17 October 2026
Export DBVT’s income statement to Excel — free account
DBV Technologies S.A.
DBVT Healthcare Biotechnology
DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 53.3%, EPS grew 61.3% and free cash flow fell 56.2%, each against the same quarter a year earlier.
9.05
0.06
−0.66%
Follow DBVT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
288.09 | 311.97 | 94.95 | 48.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.03) | (36.45) | (15.21) | (8.44) | |
P/B ratio |
8.86 | 8.60 | 3.17 | 5.18 | |
Price to Tangible BV |
8.87 | 8.61 | 3.17 | 5.18 | |
EV/Sales |
252.69 | 272.04 | 60.52 | 36.52 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.37) | (10.36) | (2.81) | (2.08) | |
EV/FCF |
(7.31) | (10.29) | (2.80) | (2.07) | |
Quick Ratio |
3.22 | 4.42 | 3.35 | 1.41 | |
Current Ratio |
3.72 | 4.76 | 3.67 | 1.80 | |
Net Debt/EBITDA |
3.50 | 4.89 | 4.38 | 2.09 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.04 | 0.05 | |
Operating CF/Net income |
1.04 | 1.03 | 0.79 | 0.98 | |
Capex/Depreciation |
(0.67) | (0.44) | (0.55) | (0.20) | |
Interest Coverage |
— | 95.60 | — | 30.80 | |
Research and Development Expense of Revenue |
4,457.14% | 3,711.11% | 5,848.22% | 1,031.54% | |
Selling, General and Administrative Expense of Revenue |
2,871.43% | 1,700.00% | 2,272.78% | 304.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
528.57% | 255.56% | 342.35% | 20.30% | |
Graham Net Nets |
0.10 | 0.11 | 0.28 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.40%) | (21.35%) | (27.23%) | (51.70%) | |
Free Cash Flow Yield |
(12.00%) | (8.47%) | (22.76%) | (35.95%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.10 | |
Operating CF per Share |
(0.61) | (0.57) | (1.26) | (1.18) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.61) | (0.58) | (1.27) | (1.19) | |
Cash per Share |
2.02 | 2.68 | 6.96 | 2.55 | |
Shareholders Equity per Share |
1.85 | 2.43 | 6.05 | 1.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.85 | 2.43 | 6.05 | 1.93 | |
Free Cash Flow |
(53.00) | (49.50) | (35.55) | (32.57) | |
Working Capital |
147.60 | 194.90 | 154.90 | 39.40 | |
Capital Expenditures |
(0.40) | (0.40) | (0.38) | (0.16) | |
Net Current Asset Value |
139.10 | 188.30 | 148.00 | 31.24 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.57 | 0.44 | 0.67 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
40.10 | 36.82 | 31.47 | 31.16 | |
Average Assets |
183.31 | 158.48 | 149.68 | 101.78 | |
Average Common Equity |
123.36 | 105.44 | 98.14 | 53.44 |
Columns are period end dates